Core Insights - Genmab A/S is a biotech innovator focusing on antibody engineering and has a strategy that includes direct commercialization of its products Tivdak and Epcoritamab, as well as monetizing through partnerships and licensing drugs like Darzalex and Kesimpta [1] Group 1 - The company retains its value through innovative antibody engineering [1] - Genmab's strategy involves both direct product sales and partnerships for drug monetization [1]

Financial Data and Key Metrics Changes - Total revenues for Q3 2020 were $1.1 billion, with year-to-date revenues of $1.6 billion [21] - Product sales reached $267 million in Q3, with year-to-date product sales of $706 million [21] - Collaboration revenues significantly increased to $758 million in Q3, compared to $18 million in the same period of 2019 [22] - The company ended Q3 with $1.7 billion in cash and investments, bolstered by $725 million in upfront payments from Merck [25][26] Business Line Data and Key Metrics Changes - ADCETRIS sales were $163 million in Q3, a 3% decrease from Q3 2019, attributed to the pandemic's impact on new diagnoses [16][18] - PADCEV sales were $62 million in Q3, an 8% increase over Q2 2020, indicating strong adoption in both academic and community settings [19] - TUKYSA generated $42 million in net product revenues in its first full quarter since launch, with strong adoption and reimbursement coverage exceeding expectations [20] Market Data and Key Metrics Changes - The pandemic has led to a 15% decrease in new Hodgkin lymphoma diagnoses, impacting ADCETRIS sales [16][18] - The company is seeing a shift in site of care that negatively affected gross to net pricing for ADCETRIS [17] - The collaboration with Merck is expected to enhance global reach and patient access for TUKYSA and LV [10] Company Strategy and Development Direction - The company aims to invest in clinical development for ADCETRIS, PADCEV, and TUKYSA, while advancing late-stage pipeline products [12] - Strategic collaborations with Merck are focused on co-developing LV and TUKYSA, enhancing the company's market position [10][12] - The company plans to continue expanding its international infrastructure to support TUKYSA's launch in Europe [9] Management's Comments on Operating Environment and Future Outlook - Management expressed concern over the long-term impact of COVID-19 on cancer patient diagnoses and treatment [48][49] - The company remains optimistic about maintaining market share despite the pandemic's challenges [49] - Future guidance for ADCETRIS has been adjusted to $650 million to $660 million due to fewer new patient diagnoses [26] Other Important Information - The company is pursuing legal action against Daichi Sankyo for patent infringement related to a breast cancer drug [13] - Upcoming R&D Day is scheduled for November 16, where the company will discuss its pipeline and development activities [12] Q&A Session Summary Question: Can you comment on ADCETRIS market dynamics and diagnosis rates? - Management noted that product sales have increased year-over-year, but the pandemic has led to fewer patients starting treatment, which is concerning for future diagnoses [48][49] Question: What is the outlook for PADCEV's growth? - Management indicated that the launch has been strong, and while there may be a slight slowdown in growth, they are maintaining guidance and expect significant developments ahead [54][56] Question: Can you provide details on TUKYSA's launch and adoption hurdles? - The company reported strong uptake in both community and academic settings, with ongoing efforts to enhance awareness and access despite COVID-19 challenges [72][73] Question: How does the cash influx from Merck affect capital allocation? - Management emphasized that the priority is to drive existing products into blockbuster status while exploring new drug opportunities and maintaining innovation [89][92]

Company Announcement - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,237 million in Q1 2025, with USD 1,829 million from the U.S. and USD 1,409 million from the rest of the world [1][5] - Genmab receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] About Genmab - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives, with a vision to transform cancer treatment by 2030 [2] - The company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators [2] Company Background - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a presence in North America, Europe, and Asia Pacific [3]

Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from March 31 to April 4, 2025: Trading PlatformNo. of sharesAverage price (D ...

Core Insights - The European Commission has approved an indication extension for DARZALEX® (daratumumab) subcutaneous formulation in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients [1][3] - The Phase 3 CEPHEUS study demonstrated significant improvements in minimal residual disease (MRD)-negativity rate, progression-free survival, and complete response rates compared to standard care [1][4] Company Overview - Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has been a leader in multiple myeloma treatment for over 20 years, with daratumumab becoming a foundational therapy used in over 618,000 patients globally [6][7] - The company aims to provide access to daratumumab-based regimens for all patient populations, regardless of age or fitness, marking a critical step towards achieving a functional cure for multiple myeloma [3][6] Clinical Study Findings - The CEPHEUS study involved 395 patients with newly diagnosed multiple myeloma who were ineligible for stem cell transplantation, comparing daratumumab-VRd to standard VRd [4][5] - At a median follow-up of 59 months, the MRD-negativity rate was 60.9% for daratumumab-VRd versus 39.4% for VRd, with a significant odds ratio of 2.37 [1][4] - The study also reported a 43% reduction in the risk of progression or death with daratumumab-VRd compared to VRd, with median progression-free survival not reached for daratumumab-VRd [1][4] Safety Profile - The safety profile of daratumumab-VRd aligns with known safety profiles for daratumumab SC and VRd, with common Grade 3/4 adverse events including neutropenia (44.2% vs 29.7% for VRd) and thrombocytopenia (28.4% vs 20.0% for VRd) [2][4]

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of daratumumab subcutaneous (SC) formulation for newly diagnosed multiple myeloma (NDMM), which would make it the only anti-CD38 therapy available for all patient types in the frontline setting [1][2][5]. Group 1: Company Developments - Janssen-Cilag International NV, a Johnson & Johnson company, announced the CHMP's positive recommendation for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone for adult patients with NDMM [1][5]. - The recommendation is based on the results from the Phase 3 CEPHEUS study, which demonstrated improved progression-free survival for patients receiving daratumumab-VRd compared to standard VRd [1][2][5]. - Daratumumab has been a foundational therapy in multiple myeloma treatment, with over 618,000 patients treated globally since its launch [5][6]. Group 2: Study Insights - The CEPHEUS study (NCT03652064) is an international, randomized, open-label Phase 3 trial that enrolled 395 patients with NDMM who were ineligible for stem cell transplantation [2][5]. - The primary endpoint of the study was the overall Minimal Residual Disease (MRD) negativity rate, with a median patient age of 70 years [2][5]. - Results from the CEPHEUS study were presented at the 2024 International Myeloma Society Annual Meeting and the 2024 American Society of Hematology Annual Meeting [1][2]. Group 3: Product Information - Daratumumab is the only CD38-directed antibody approved for subcutaneous administration in multiple myeloma treatment [5][6]. - The drug works by binding to CD38, a surface protein present on myeloma cells, inhibiting tumor cell growth and causing myeloma cell death [5][6]. - Data from ten Phase 3 clinical trials have shown significant improvements in progression-free survival and/or overall survival with daratumumab-based regimens [5][6].